If ASOs or other small molecular inhibitors are designed for the combination of MBNL1/Myocardin and MBNL1/TNF‐α, it may be possible to inhibit cardiac hypertrophy and prevent the apoptosis of cardiomyocytes. This evidence concerns the gene MYOCD and cardiac hypertrophy.